Heart Failure Reviews最新文献_第5页

Biosensors with left ventricular assist devices. 带有左心室辅助装置的生物传感器。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-06-28 DOI: 10.1007/s10741-024-10413-x

Mahmoud Abbassy, Muhammad Zain Ali, Riya Manas Sharma, Yohan Porus Irani, Adil Dahlan, Maimoona Azhar, Nadeem Aslam, Babar Hasan, Aamir Hameed

{"title":"Biosensors with left ventricular assist devices.","authors":"Mahmoud Abbassy, Muhammad Zain Ali, Riya Manas Sharma, Yohan Porus Irani, Adil Dahlan, Maimoona Azhar, Nadeem Aslam, Babar Hasan, Aamir Hameed","doi":"10.1007/s10741-024-10413-x","DOIUrl":"10.1007/s10741-024-10413-x","url":null,"abstract":"Heart failure imposes a significant global health burden, standing as a primary contributor to mortality. Various indicators and physiological shifts within the body may hint at distinct cardiac conditions. Specific biosensors have the capability to identify these changes. Integrating or embedding these biosensors into mechanical circulatory support devices (MCSDs), such as left ventricular assist devices (LVADs), becomes crucial for monitoring alterations in biochemical and physiological factors subsequent to an MCSD implantation. Detecting abnormal changes early in the course of disease progression will allow for improved patient outcomes and prognosis following an MCSD implantation. The aim of this review is to explore the available biosensors that may be coupled or implanted alongside LVADs to monitor biomarkers and changes in physiological parameters. Different fabrication materials for the biosensors are discussed, including their advantages and disadvantages. This review also examines the feasibility of integrating feedback control mechanisms into LVAD systems using data from the biosensors. Challenges facing this emerging technology and future directions for research and development are outlined as well. The overarching goal is to provide an overview of how implanted biosensors may improve the performance and outcomes of LVADs through continuous monitoring and closed-loop control.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nexilin in cardiomyopathy: unveiling its diverse roles with special focus on endocardial fibroelastosis. 心肌病中的 Nexilin：揭示其多种作用，特别关注心内膜纤维细胞增生。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1007/s10741-024-10416-8

Mahsa Rahimzadeh, Stephanie Tennstedt, Zouhair Aherrahrou

{"title":"Nexilin in cardiomyopathy: unveiling its diverse roles with special focus on endocardial fibroelastosis.","authors":"Mahsa Rahimzadeh, Stephanie Tennstedt, Zouhair Aherrahrou","doi":"10.1007/s10741-024-10416-8","DOIUrl":"10.1007/s10741-024-10416-8","url":null,"abstract":"Cardiac disorders exhibit considerable heterogeneity, and understanding their genetic foundations is crucial for their diagnosis and treatment. Recent genetic analyses involving a growing number of participants have uncovered novel mutations within both coding and non-coding regions of DNA, contributing to the onset of cardiac conditions. The NEXN gene, encoding the Nexilin protein, an actin filament-binding protein, is integral to normal cardiac function. Mutations in this gene have been linked to cardiomyopathies, cardiovascular disorders, and sudden deaths. Heterozygous or homozygous variants of the NEXN gene are associated with the development of endocardial fibroelastosis (EFE), a rare cardiac condition characterized by excessive collagen and elastin deposition in the left ventricular endocardium predominantly affecting infants and young children. EFE occurs both primary and secondary to other conditions and often leads to unfavorable prognoses and outcomes. This review explores the role of NEXN genetic variants in cardiovascular disorders, particularly EFE, revealing that functional mutations are not clustered in a specific domain of Nexilin based on the cardiac disorder phenotype. Our review underscores the importance of understanding genetic mutations for the diagnosis and treatment of cardiac conditions.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The significance of the apelinergic system in doxorubicin-induced cardiotoxicity. 凋亡素能系统在多柔比星诱导的心脏毒性中的重要作用

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1007/s10741-024-10414-w

Katarzyna Matusik, Katarzyna Kamińska, Aleksandra Sobiborowicz-Sadowska, Hubert Borzuta, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska

{"title":"The significance of the apelinergic system in doxorubicin-induced cardiotoxicity.","authors":"Katarzyna Matusik, Katarzyna Kamińska, Aleksandra Sobiborowicz-Sadowska, Hubert Borzuta, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska","doi":"10.1007/s10741-024-10414-w","DOIUrl":"10.1007/s10741-024-10414-w","url":null,"abstract":"Cancer is the leading cause of death worldwide, and the number of cancer-related deaths is expected to increase. Common types of cancer include skin, breast, lung, prostate, and colorectal cancers. While clinical research has improved cancer therapies, these treatments often come with significant side effects such as chronic fatigue, hair loss, and nausea. In addition, cancer treatments can cause long-term cardiovascular complications. Doxorubicin (DOX) therapy is one example, which can lead to decreased left ventricle (LV) echocardiography (ECHO) parameters, increased oxidative stress in cellular level, and even cardiac fibrosis. The apelinergic system, specifically apelin and its receptor, together, has shown properties that could potentially protect the heart and mitigate the damages caused by DOX anti-cancer treatment. Studies have suggested that stimulating the apelinergic system may have therapeutic benefits for heart damage induced by DOX. Further research in chronic preclinical models is needed to confirm this hypothesis and understand the mechanism of action for the apelinergic system. This review aims to collect and present data on the effects of the apelinergic system on doxorubicin-induced cardiotoxicity.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials. 急性心力衰竭患者的乙酰唑胺治疗：随机对照试验的系统回顾和荟萃分析。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1007/s10741-024-10417-7

Tanize Louize Milbradt, Renan Yuji Ura Sudo, Marília Oberto da Silva Gobbo, Stephen Akinfenwa, Brenda Moura

{"title":"Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials.","authors":"Tanize Louize Milbradt, Renan Yuji Ura Sudo, Marília Oberto da Silva Gobbo, Stephen Akinfenwa, Brenda Moura","doi":"10.1007/s10741-024-10417-7","DOIUrl":"10.1007/s10741-024-10417-7","url":null,"abstract":"Acute heart failure (AHF) often leads to unfavorable outcomes due to fluid overload. While diuretics are the cornerstone treatment, acetazolamide may enhance diuretic efficiency by reducing sodium reabsorption. We performed a systematic review and meta-analysis on the effects of acetazolamide as an add-on therapy in patients with AHF compared to diuretic therapy. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCT). A random-effects model was employed to compute mean differences and risk ratios. Statistical analysis was performed using R software. The GRADE approach was used to rate the certainty of the evidence. We included 4 RCTs with 634 patients aged 68 to 81 years. Over a mean follow-up of 3 days to 34 months, acetazolamide significantly increased diuresis (MD 899.2 mL; 95% CI 249.5 to 1549; p < 0.01) and natriuresis (MD 72.44 mmol/L; 95% CI 39.4 to 105.4; p < 0.01) after 48 h of its administration. No association was found between acetazolamide use and WRF (RR 2.4; 95% CI 0.4 to 14.2; p = 0.3) or all-cause mortality (RR 1.2; 95% CI 0.8 to 1.9; p = 0.3). Clinical decongestion was significantly higher in the intervention group (RR 1.35; 95% CI 1.09 to 1.68; p = 0.01). Acetazolamide is an effective add-on therapy in patients with AHF, increasing diuresis, natriuresis, and clinical decongestion, but it was not associated with differences in mortality.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ex vivo heart perfusion: an updated systematic review. 体外心脏灌注：最新系统综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI: 10.1007/s10741-024-10420-y

Nicola Pradegan, Luigi Di Pasquale, Dario Di Perna, Michele Gallo, Giovanni Lucertini, Marco Gemelli, Thomas Beyerle, Mark S Slaughter, Gino Gerosa

引用次数: 0

High-intensity care for GDMT titration. 为 GDMT 滴定提供高强度护理。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI: 10.1007/s10741-024-10419-5

Jan Biegus, Matteo Pagnesi, Beth Davison, Piotr Ponikowski, Alexander Mebazaa, Gadi Cotter

引用次数: 0

Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS. 治疗射血分数保留型心力衰竭的抗肥胖药物：现有证据和下一步行动。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI: 10.1007/s10741-024-10410-0

Josephine Harrington

引用次数: 0

Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial. 选择性醛糖还原酶抑制作为糖尿病心肌病的治疗方法：ARISE-HF 试验摘要。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-25 DOI: 10.1007/s10741-024-10427-5

Laibah Arshad Khan, Muhammad Shahzeb Khan, Andrew P Ambrosy, Stephen J Greene

引用次数: 0

The role of NETosis in heart failure. NETosis 在心力衰竭中的作用

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-07-29 DOI: 10.1007/s10741-024-10421-x

Sawa Kostin, Florian Krizanic, Theodoros Kelesidis, Nikolaos Pagonas

{"title":"The role of NETosis in heart failure.","authors":"Sawa Kostin, Florian Krizanic, Theodoros Kelesidis, Nikolaos Pagonas","doi":"10.1007/s10741-024-10421-x","DOIUrl":"10.1007/s10741-024-10421-x","url":null,"abstract":"The hallmark of heart failure (HF) is structural myocardial remodeling including cardiomyocyte hypertrophy, fibrosis, cardiomyocyte cell death, and a low-grade aseptic inflammation. The initiation and maintenance of persistent chronic low-grade inflammation in HF are not fully understood. Oxidative stress-mediated neutrophil extracellular traps (NETs) are the main immune defense mechanism against external bacterial infections. Furthermore, NETs play important roles in noninfectious diseases. In the settings of myocardial infarction, myocarditis, or cardiomyopathies, neutrophils infiltrate the cardiac tissue and undergo NETosis that further aggravate the inflammation. A number of stimuli may cause NETosis that is a form of programmed cell death of neutrophils that is different from apoptosis of these cells. Whether NETosis is directly involved in the pathogenesis and development of HF is still unclear. In this review, we analyzed the mechanisms and markers of NETosis, especially placing the accent on the activation of the neutrophil-specific myeloperoxidase (MPO), elastase (NE), and peptidylarginine deiminase 4 (PAD4). These conclusions are supported by the recent genetic and pharmacological studies which demonstrated that MPO, NE, and PAD4 inhibitors are effective at least in the settings of post-myocardial infarction adverse remodeling, cardiac valve diseases, cardiomyopathies, and decompensated left ventricular hypertrophy whose deterioration can lead to HF. This is essential for understanding NETosis as a contributor to pathophysiology of HF and developments of new therapies of HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the penetrance and phenotypic spectrum of inherited cardiomyopathies. 探索遗传性心肌病的渗透性和表型谱。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2024-09-01 Epub Date: 2024-06-19 DOI: 10.1007/s10741-024-10405-x

Frans Serpa, Caitlin M Finn, Usman A Tahir

引用次数: 0